Join Growin Stock Community!

Tharimmune, inc.THAR.US Overview

US StockHealthcare
(No presentation for THAR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

THAR AI Insights

THAR Overall Performance

THAR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

THAR Recent Performance

-

Tharimmune, inc.

0.05%

Avg of Sector

-0.31%

S&P500

THAR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

THAR Key Information

THAR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

THAR Profile

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Price of THAR

THAR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

THAR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.26
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
32.18
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.26
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
32.18
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is THAR's latest earnings report released?

    The most recent financial report for Tharimmune, inc. (THAR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating THAR's short-term business performance and financial health. For the latest updates on THAR's earnings releases, visit this page regularly.

  • How much cash does THAR have?

    At the end of the period, Tharimmune, inc. (THAR) held Total Cash and Cash Equivalents of 7.61M, accounting for 0.99 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is THAR's EPS continuing to grow?

    According to the past four quarterly reports, Tharimmune, inc. (THAR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.34. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of THAR?

    Tharimmune, inc. (THAR)'s Free Cash Flow (FCF) for the period is -1.86M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 35.22% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.